Home > News > Top Stories > Xenex Announces World’s First Disinfection Tracking System

Digital Healthcare, Healthcare Analytics

Xenex Announces World’s First Disinfection Tracking System

Xenex Announces World’s First

Portable Medical Equipment (PME) such as IV pumps, workstations on wheels (WOWs), and vitals machines can carry and transfer dangerous pathogens between rooms and patients within healthcare facilities because the equipment is often used and rolled between multiple patient rooms. Recognizing the importance of being able to track and report disinfection, Xenex Disinfection Services today announced TrackMate™, a patented device developed by hospitals for hospitals that provides automated tracking of disinfection/cleaning events for PME and hospital rooms. It’s the world’s first automated tracking system and solution for The Joint Commission standard IC 02.02.01 EP1, which focuses on the disinfection of PME.

TrackMate is a small, easy-to-use device that attaches to PME and registers each disinfection\cleaning event stores the data in a secure portal, and provides the data that can be used for compliance and The Joint Commission reporting.

Peer-reviewed studies demonstrated that twice as many PME disinfection events occurred when TrackMate was deployed and 100% of disinfection events were tracked and reported for compliance. TrackMate replaces low tech and often labor-intensive monitoring solutions currently being used in healthcare facilities, such as equipment tags, clipboards and paper checklists, and plastic bags placed over IV poles. It eliminates the need for the manual collection of disinfection event data for Joint Commission compliance reporting.

In addition to tracking disinfection events for PME and rooms, TrackMate can be used anywhere there is a need for tracking disinfection/cleaning, logging of cleaning activity, or automated and remote monitoring of cleaning activity. For example, tracking the cleaning of surfaces in patient rooms, emergency and waiting rooms, nurse stations, kitchens, microbiology laboratories and mannequins in simulation centers.

“Healthcare workers can’t look at an IV pole and know when it was last disinfected, which is why TrackMate is such a game changer. For the first time, disinfection/cleaning event status is being delivered to the user at the point of care. Nurses can quickly look at TrackMate and see when the last disinfection/cleaning event occurred. The CDC has stated that Candida auris is commonly spread via PME – so it’s incredibly important to know when the PME was last cleaned. Infection preventionists and hospital compliance personnel are going to be very excited to learn that we have a solution to IC 02.02.01,” said Dr. Mark “Tuck” Stibich, co-founder and Chief Scientific Officer of Xenex.

TrackMate was invented by Dr. Chetan Jinadatha, Chief of the Infectious Diseases Division at the Central Texas Veterans Health Care System and Clinical Professor, School of Medicine, Texas A&M University. Commercialization of TrackMate is supported by the VA Technology Transfer Program, which facilitates the commercialization of VA inventions to benefit Veterans and the American public. Funding from the National Institutes of Health (NIH) and Central Texas Veterans Healthcare System supported scientific evaluation of the technology.

TrackMate is a small (2”x5”) device that attaches to PME or can be placed in a room. It senses moisture (wipes) or UV light irradiation, collects all of the disinfection/cleaning events and keeps a log locally and online. Events are transmitted once a day through cellular signal to an online database. Supervisors can log in and retrieve the cleaning log for improving cleaning practices or validate compliance with policy. Battery life on each device is 3 years.

About Xenex Disinfection Services

Xenex is a world leader in innovative UV technology-based disinfection strategies and solutions. Xenex's mission is to enable its partners to save lives and reduce suffering by destroying the deadly microorganisms that can cause infections. Xenex is backed by well-known investors that include EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures and RK Ventures.

Spotlight

More featured news

Spotlight

Related News

Health Technology, Digital Healthcare

Best Buy Health and Geisinger Enhance Home Chronic Disease Management

Geisinger | September 13, 2023

Collaborating with Best Buy's Geek Squad ensures faster care, better adherence, and superior outcomes for chronic care patients. In 2021, Geisinger launched ConnectedCare365, enrolling over 1,100 patients in remote monitoring for various chronic conditions via Best Buy Health's Current Health platform. In July 2022, Best Buy Health and Geisinger began a program with Geek Squad Agents to deliver and activate remote care management devices. Best Buy Health and Geisinger have announced their commitment to expand their collaborative efforts to enhance the quality of care for a broader patient population within the Geisinger network. This expansion builds upon their successful delivery of in-home care to patients with chronic conditions through Geek Squad. This initiative currently encompasses 300 Geisinger patients. During their home visits, these agents critically educate patients about the technology integral to their care plan. They offer detailed explanations about the devices, instruct patients on proper usage, and ensure seamless data transmission to the patient's care team. Additionally, agents are available to help with troubleshooting as needed, and they oversee the collection and processing of all devices after a patient leaves the program, following the care team's instructions. The program has achieved a remarkable 50% reduction in the time it takes for a patient to go from admission into the chronic care at-home program to the completion of device setup. This pivotal shift has seen the period shrink from an average of 96 hours to just 48 hours. Furthermore, patients' adherence to their care plans has improved by a commendable 19%, evident in their consistent use of remote technology equipment. Additionally, there has been an 18% decline in reported technical issues, and when replacements were necessary, Geek Squad agents swiftly provided new devices within 24 hours of receiving reports. These exceptional results have garnered positive patient feedback, with a net promoter score of 89 when asked about their experience with Geek Squad's home visits for chronic care program setup. Deborah Di Sanzo, President of Best Buy Health, stated, The results of our program show that when we combine what Best Buy is known for—technology support and expertise—with Geisinger's best-in-class care teams and network of clinics and hospitals, we can make a meaningful difference in the patient and caregiver experience. [Source: Business Wire] Additionally, she emphasized Geisinger's outstanding performance on this initiative. She expressed strong enthusiasm for expanding these capabilities nationwide, in alignment with Best Buy Health's mission to promote accessible at-home care for everyone. Karen Murphy, EVP, Chief Innovation Officer and Founding Director of the Steele Institute for Health Innovation at Geisinger, emphasized the dynamic changes in healthcare. She highlighted the organization's heightened dedication to bringing care closer to patients and members while striving to establish higher care quality standards. The collaboration with Best Buy Health has enabled Geisinger to reshape the healthcare experience, ushering in positive transformations in care delivery and reception. Best Buy aims to enhance lives through technology by providing customers with expert guidance, a diverse product range, and comprehensive in-store and online services. Meanwhile, Geisinger dedicates itself to simplifying the journey to improved health for its extensive community of over one million individuals.

Read More

Health Technology, Medical Devices

GE HealthCare Receives FDA Clearance of Allia IGS Pulse - the Next Generation of Image-Guided Systems Designed for Cardiac Imaging Excellence

Business Wire | October 18, 2023

GE HealthCare announced US FDA 510(k) clearance of Allia IGS Pulse - the latest addition to the company’s image guided system (IGS) offerings. Allia IGS Pulse features a new imaging chain engineered to provide exceptional imaging at the right dose for visible impact in complex cardiology interventions regardless of patient size. In modern healthcare today, cardiovascular disease (CVD) continues to grow in prevalence, with CVDs being the leading cause of death globally. As clinicians work to treat CVDs, cardiology procedures continue to evolve as demand for minimally invasive surgery grows. GE HealthCare is committed to helping interventional cardiologists, vascular surgeons and other interventional specialists use image guidance technologies to their full potential by optimizing workflows and providing exceptional image quality to help clinicians provide quality care to their patients, while also enabling better clinical and operational outcomes. According to a survey of interventionalists, nearly 50% of interventional procedures are performed at working positions where clinicians have poor access to user interface functions and display.3 Designed to address these challenges, the new Allia IGS Pulse provides a personalized workspace that meets the operator’s specific needs and preferences. As part of its new image chain, the system features the first monopolar x-ray tube used to capture images for interventional procedures. This new tube is powerful, yet quieter than normal conversation4 to optimize the operating environment during a procedure. The small footprint of the new tube also helps clinicians reach steep angulation for better understanding of coronary artery anatomy, even with the 30cm detector configurations. The latest version of MyIQ technology incorporated into the system allows clinicians to select their favorite image look from four different image styles with just one click for a tailored experience at no additional dose. In the treatment of complex cardiovascular diseases, image quality and optimized dose management regardless of patient size are also important to clinicians. With Allia IGS Pulse, interventionalists are able to get exceptional image quality for large and bariatric patients with a BMI of greater than 30. The system’s reduced pulse width and unmatched X-ray peak power helps to decrease motion blur for better visualization of moving elements such as vessels and devices. To relieve clinicians and technologists of the complex task of optimizing image quality and dose during procedures, Allia IGS Pulse takes AutoRight, the company’s intelligent image chain leveraging AI, a step further with AutoRight PLUS - the next generation of the automation platform. With AutoRight PLUS, the system now optimizes seven parameters in real time, including Focal Spot Shape. By removing the burden of manual adjustment during procedures, clinicians can stay focused on the procedure and treatment of their patients. To further optimize dose along the image chain, a unique suite of tools is also available to help support dose efficiency, dose reduction and dose awareness. Since January 2023, Allia IGS Pulse has been in pilot operations at Clinique Pasteur - Toulouse in Toulouse, France. “At Clinique Pasteur in Toulouse, we perform thousands of interventional cardiology procedures each year,” says Dr. Nicolas Dumonteil, Interventional Cardiologist, Clinique Pasteur, Toulouse. “As an operator of the Allia IGS Pulse system, I felt a significant and real improvement in the imaging quality, as well as a significant reduction of this noise in my daily procedures which gave me great confidence and comfort in the operating room. The system is also quite adaptable and versatile to all of my daily situations and procedures – from percutaneous coronary interventions (PCIs) to other complex and structural ones.” says Dr Raphaël Philippart, Interventional Cardiologist, Clinique Pasteur, Toulouse. I saw a significant improvement in the image quality, especially with obese patients and complex angioplasties - where a good visibility of my guidewire, balloons and stents are particularly important. [Source – Business Wire] “Interventional cardiology procedures require exceptional image quality,” says Arnaud Marie – General Manager of Interventional for GE HealthCare. “I’m excited by the addition of Allia IGS Pulse to our interventional offerings because it addresses the very things clinicians continue to tell us present challenges in their day-to-day practice. By developing new features to further evolve our core platform, we’re helping to reduce complexity and improve the operating environment so that clinicians can have a personalized workspace that better enables them to keep their focus where it belongs – on their patients.”

Read More

Health Technology, Digital Healthcare

Johnson and Johnson Embraces New Era with Enhanced Visual Identity

Johnson and Johnson | September 15, 2023

Johnson and Johnson's brand identity communicates the company's bold healthcare innovation while staying true to its global patient care. Leveraging advanced medicine and technology, the company proactively tackles complex diseases with more innovative, less invasive, and personalized solutions. The company plans to gradually implement the new logo, colors, and font across all its materials, product packaging, and branding assets. Johnson and Johnson is currently revitalizing its brand and consolidating its MedTech and pharmaceutical segments under the unified name of Johnson and Johnson, demonstrating a steadfast commitment to healthcare innovation and addressing the most challenging health issues. The announcement signifies a pivotal moment in Johnson and Johnson's evolution as the company harnesses its extensive knowledge of innovative medicine and cutting-edge medical technology. This strategic move aims to proactively address, treat, and ultimately find cures for intricate diseases while simultaneously ushering in solutions characterized by heightened intelligence, reduced invasiveness, and greater personalization, marking a significant stride toward reshaping the future of healthcare. The company's two major segments will become more closely associated with the Johnson and Johnson brand. Over time, Janssen, the company's pharmaceutical part, will assume the name Johnson and Johnson Innovative Medicine, while the medical technology segment will retain the Johnson and Johnson MedTech designation. The pharmaceuticals segment leads the way in advancing healthcare, pioneering treatments to reshape the future of well-being. Johnson and Johnson Innovative Medicine combines a compassionate scientific approach to effectively confront the most complex diseases in oncology, immunology, neuroscience, cardiovascular, pulmonary hypertension, and retina to develop future medications. Simultaneously, the medical technology segment dedicates itself to addressing the most pressing healthcare challenges through innovations at the nexus of biology and technology. Vanessa Broadhurst, Executive Vice President of Global Corporate Affairs, stated, Our Johnson and Johnson brand identity communicates our bold approach to innovation in healthcare while staying true to the care we have for our patients around the world. [Source: Business Wire] The updated Johnson and Johnson logo, featuring letters drawn in a single stroke for added contrast and a sense of unexpectedness, embraces both long and short versions, with the 'J&J' abbreviation gaining prominence, especially in digital contexts. The color palette leans toward a refreshed and contemporary red, symbolizing the company's agility in responding to health challenges and evolving with the times. The revamped ampersand now signifies global recognition, openness, and the connections that breathe life into the brand's purpose. In terms of art direction, elements such as illustration and photography have undergone careful curation to evoke energy, optimism, and inclusivity, presenting a distinctive approach within the healthcare domain.

Read More

Health Technology, Digital Healthcare

Best Buy Health and Geisinger Enhance Home Chronic Disease Management

Geisinger | September 13, 2023

Collaborating with Best Buy's Geek Squad ensures faster care, better adherence, and superior outcomes for chronic care patients. In 2021, Geisinger launched ConnectedCare365, enrolling over 1,100 patients in remote monitoring for various chronic conditions via Best Buy Health's Current Health platform. In July 2022, Best Buy Health and Geisinger began a program with Geek Squad Agents to deliver and activate remote care management devices. Best Buy Health and Geisinger have announced their commitment to expand their collaborative efforts to enhance the quality of care for a broader patient population within the Geisinger network. This expansion builds upon their successful delivery of in-home care to patients with chronic conditions through Geek Squad. This initiative currently encompasses 300 Geisinger patients. During their home visits, these agents critically educate patients about the technology integral to their care plan. They offer detailed explanations about the devices, instruct patients on proper usage, and ensure seamless data transmission to the patient's care team. Additionally, agents are available to help with troubleshooting as needed, and they oversee the collection and processing of all devices after a patient leaves the program, following the care team's instructions. The program has achieved a remarkable 50% reduction in the time it takes for a patient to go from admission into the chronic care at-home program to the completion of device setup. This pivotal shift has seen the period shrink from an average of 96 hours to just 48 hours. Furthermore, patients' adherence to their care plans has improved by a commendable 19%, evident in their consistent use of remote technology equipment. Additionally, there has been an 18% decline in reported technical issues, and when replacements were necessary, Geek Squad agents swiftly provided new devices within 24 hours of receiving reports. These exceptional results have garnered positive patient feedback, with a net promoter score of 89 when asked about their experience with Geek Squad's home visits for chronic care program setup. Deborah Di Sanzo, President of Best Buy Health, stated, The results of our program show that when we combine what Best Buy is known for—technology support and expertise—with Geisinger's best-in-class care teams and network of clinics and hospitals, we can make a meaningful difference in the patient and caregiver experience. [Source: Business Wire] Additionally, she emphasized Geisinger's outstanding performance on this initiative. She expressed strong enthusiasm for expanding these capabilities nationwide, in alignment with Best Buy Health's mission to promote accessible at-home care for everyone. Karen Murphy, EVP, Chief Innovation Officer and Founding Director of the Steele Institute for Health Innovation at Geisinger, emphasized the dynamic changes in healthcare. She highlighted the organization's heightened dedication to bringing care closer to patients and members while striving to establish higher care quality standards. The collaboration with Best Buy Health has enabled Geisinger to reshape the healthcare experience, ushering in positive transformations in care delivery and reception. Best Buy aims to enhance lives through technology by providing customers with expert guidance, a diverse product range, and comprehensive in-store and online services. Meanwhile, Geisinger dedicates itself to simplifying the journey to improved health for its extensive community of over one million individuals.

Read More

Health Technology, Medical Devices

GE HealthCare Receives FDA Clearance of Allia IGS Pulse - the Next Generation of Image-Guided Systems Designed for Cardiac Imaging Excellence

Business Wire | October 18, 2023

GE HealthCare announced US FDA 510(k) clearance of Allia IGS Pulse - the latest addition to the company’s image guided system (IGS) offerings. Allia IGS Pulse features a new imaging chain engineered to provide exceptional imaging at the right dose for visible impact in complex cardiology interventions regardless of patient size. In modern healthcare today, cardiovascular disease (CVD) continues to grow in prevalence, with CVDs being the leading cause of death globally. As clinicians work to treat CVDs, cardiology procedures continue to evolve as demand for minimally invasive surgery grows. GE HealthCare is committed to helping interventional cardiologists, vascular surgeons and other interventional specialists use image guidance technologies to their full potential by optimizing workflows and providing exceptional image quality to help clinicians provide quality care to their patients, while also enabling better clinical and operational outcomes. According to a survey of interventionalists, nearly 50% of interventional procedures are performed at working positions where clinicians have poor access to user interface functions and display.3 Designed to address these challenges, the new Allia IGS Pulse provides a personalized workspace that meets the operator’s specific needs and preferences. As part of its new image chain, the system features the first monopolar x-ray tube used to capture images for interventional procedures. This new tube is powerful, yet quieter than normal conversation4 to optimize the operating environment during a procedure. The small footprint of the new tube also helps clinicians reach steep angulation for better understanding of coronary artery anatomy, even with the 30cm detector configurations. The latest version of MyIQ technology incorporated into the system allows clinicians to select their favorite image look from four different image styles with just one click for a tailored experience at no additional dose. In the treatment of complex cardiovascular diseases, image quality and optimized dose management regardless of patient size are also important to clinicians. With Allia IGS Pulse, interventionalists are able to get exceptional image quality for large and bariatric patients with a BMI of greater than 30. The system’s reduced pulse width and unmatched X-ray peak power helps to decrease motion blur for better visualization of moving elements such as vessels and devices. To relieve clinicians and technologists of the complex task of optimizing image quality and dose during procedures, Allia IGS Pulse takes AutoRight, the company’s intelligent image chain leveraging AI, a step further with AutoRight PLUS - the next generation of the automation platform. With AutoRight PLUS, the system now optimizes seven parameters in real time, including Focal Spot Shape. By removing the burden of manual adjustment during procedures, clinicians can stay focused on the procedure and treatment of their patients. To further optimize dose along the image chain, a unique suite of tools is also available to help support dose efficiency, dose reduction and dose awareness. Since January 2023, Allia IGS Pulse has been in pilot operations at Clinique Pasteur - Toulouse in Toulouse, France. “At Clinique Pasteur in Toulouse, we perform thousands of interventional cardiology procedures each year,” says Dr. Nicolas Dumonteil, Interventional Cardiologist, Clinique Pasteur, Toulouse. “As an operator of the Allia IGS Pulse system, I felt a significant and real improvement in the imaging quality, as well as a significant reduction of this noise in my daily procedures which gave me great confidence and comfort in the operating room. The system is also quite adaptable and versatile to all of my daily situations and procedures – from percutaneous coronary interventions (PCIs) to other complex and structural ones.” says Dr Raphaël Philippart, Interventional Cardiologist, Clinique Pasteur, Toulouse. I saw a significant improvement in the image quality, especially with obese patients and complex angioplasties - where a good visibility of my guidewire, balloons and stents are particularly important. [Source – Business Wire] “Interventional cardiology procedures require exceptional image quality,” says Arnaud Marie – General Manager of Interventional for GE HealthCare. “I’m excited by the addition of Allia IGS Pulse to our interventional offerings because it addresses the very things clinicians continue to tell us present challenges in their day-to-day practice. By developing new features to further evolve our core platform, we’re helping to reduce complexity and improve the operating environment so that clinicians can have a personalized workspace that better enables them to keep their focus where it belongs – on their patients.”

Read More

Health Technology, Digital Healthcare

Johnson and Johnson Embraces New Era with Enhanced Visual Identity

Johnson and Johnson | September 15, 2023

Johnson and Johnson's brand identity communicates the company's bold healthcare innovation while staying true to its global patient care. Leveraging advanced medicine and technology, the company proactively tackles complex diseases with more innovative, less invasive, and personalized solutions. The company plans to gradually implement the new logo, colors, and font across all its materials, product packaging, and branding assets. Johnson and Johnson is currently revitalizing its brand and consolidating its MedTech and pharmaceutical segments under the unified name of Johnson and Johnson, demonstrating a steadfast commitment to healthcare innovation and addressing the most challenging health issues. The announcement signifies a pivotal moment in Johnson and Johnson's evolution as the company harnesses its extensive knowledge of innovative medicine and cutting-edge medical technology. This strategic move aims to proactively address, treat, and ultimately find cures for intricate diseases while simultaneously ushering in solutions characterized by heightened intelligence, reduced invasiveness, and greater personalization, marking a significant stride toward reshaping the future of healthcare. The company's two major segments will become more closely associated with the Johnson and Johnson brand. Over time, Janssen, the company's pharmaceutical part, will assume the name Johnson and Johnson Innovative Medicine, while the medical technology segment will retain the Johnson and Johnson MedTech designation. The pharmaceuticals segment leads the way in advancing healthcare, pioneering treatments to reshape the future of well-being. Johnson and Johnson Innovative Medicine combines a compassionate scientific approach to effectively confront the most complex diseases in oncology, immunology, neuroscience, cardiovascular, pulmonary hypertension, and retina to develop future medications. Simultaneously, the medical technology segment dedicates itself to addressing the most pressing healthcare challenges through innovations at the nexus of biology and technology. Vanessa Broadhurst, Executive Vice President of Global Corporate Affairs, stated, Our Johnson and Johnson brand identity communicates our bold approach to innovation in healthcare while staying true to the care we have for our patients around the world. [Source: Business Wire] The updated Johnson and Johnson logo, featuring letters drawn in a single stroke for added contrast and a sense of unexpectedness, embraces both long and short versions, with the 'J&J' abbreviation gaining prominence, especially in digital contexts. The color palette leans toward a refreshed and contemporary red, symbolizing the company's agility in responding to health challenges and evolving with the times. The revamped ampersand now signifies global recognition, openness, and the connections that breathe life into the brand's purpose. In terms of art direction, elements such as illustration and photography have undergone careful curation to evoke energy, optimism, and inclusivity, presenting a distinctive approach within the healthcare domain.

Read More

More featured news